These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 29500136

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    Tagawa ST, Posadas EM, Bruce J, Lim EA, Petrylak DP, Peng W, Kheoh T, Maul S, Smit JW, Gonzalez MD, De Porre P, Tran N, Nanus DM.
    Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
    [Abstract] [Full Text] [Related]

  • 6. Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors.
    Fan L, Dong B, Chi C, Wang Y, Gong Y, Sha J, Pan J, Shangguan X, Huang Y, Zhou L, Xue W.
    BMC Urol; 2018 Dec 03; 18(1):110. PubMed ID: 30509237
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration.
    Freedland SJ, Sandin R, Sah J, Emir B, Mu Q, Ratiu A, Hong A, Serfass L, Tagawa ST.
    Cancer Med; 2021 Dec 03; 10(23):8570-8580. PubMed ID: 34725947
    [Abstract] [Full Text] [Related]

  • 9. Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy.
    Kim KB, Jo JK, Ahn S, Lee S, Jeong SJ, Hong SK, Byun SS, Lee SE.
    Korean J Urol; 2015 Aug 03; 56(8):580-6. PubMed ID: 26279827
    [Abstract] [Full Text] [Related]

  • 10. The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels.
    Werutsky G, Maluf FC, Cronemberger EH, Carrera Souza V, Dos Santos Martins SP, Peixoto F, Smaletz O, Schutz F, Herchenhorn D, Santos T, Mavignier Carcano F, Queiroz Muniz D, Nunes Filho PRS, Zaffaroni F, Barrios C, Fay A.
    BMC Cancer; 2019 May 23; 19(1):487. PubMed ID: 31122212
    [Abstract] [Full Text] [Related]

  • 11. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PFA, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW.
    Eur Urol; 2017 Apr 23; 71(4):656-664. PubMed ID: 27402060
    [Abstract] [Full Text] [Related]

  • 12. Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
    Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S.
    J Med Econ; 2017 Feb 23; 20(2):121-128. PubMed ID: 27570999
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.
    Smith MR, Rathkopf DE, Mulders PF, Carles J, Van Poppel H, Li J, Kheoh T, Griffin TW, Molina A, Ryan CJ.
    J Urol; 2015 Nov 23; 194(5):1277-84. PubMed ID: 26151676
    [Abstract] [Full Text] [Related]

  • 14. Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial.
    Ohlmann CH, Jäschke M, Jaehnig P, Krege S, Gschwend J, Rexer H, Stöckle M.
    Trials; 2017 Oct 04; 18(1):457. PubMed ID: 28978327
    [Abstract] [Full Text] [Related]

  • 15. Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy.
    Manceau C, Mourey L, Pouessel D, Ploussard G.
    Expert Rev Anticancer Ther; 2020 Aug 04; 20(8):629-638. PubMed ID: 32552120
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.
    Kobayashi K, Okuno N, Arai G, Nakatsu H, Maniwa A, Kamiya N, Satoh T, Kikukawa H, Nasu Y, Uemura H, Nakashima T, Mikami K, Iinuma M, Tanabe K, Furukawa J, Kobayashi H.
    Jpn J Clin Oncol; 2021 Apr 01; 51(4):544-551. PubMed ID: 33324967
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ.
    Eur Urol; 2015 Oct 01; 68(4):570-7. PubMed ID: 25985882
    [Abstract] [Full Text] [Related]

  • 20. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S, Lang JM, Jarrard DF.
    J Urol; 2019 May 01; 201(5):876-885. PubMed ID: 30747897
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.